SSXB10 Inhibitors
SSXB10 inhibitors are a class of chemical agents defined by their interaction with the biochemical entity known as SSXB10, a protein or enzyme integral to certain cellular processes. These inhibitors are crafted to engage with the active site or a significant region of the SSXB10 structure, effectively altering its normal activity within the biological system. The design of these inhibitors is a sophisticated process, leveraging a deep understanding of the molecular architecture of SSXB10. Researchers employ advanced techniques to ensure that the inhibitors fit with high precision, thus minimizing off-target interactions with other cellular components.
The creation of SSXB10 inhibitors is a complex endeavor that combines computational modeling, the art of synthetic chemistry, and detailed biochemical testing. In silico methods provide initial insights into how these inhibitors may interact with their target, employing algorithms that model the potential binding scenarios between the inhibitor and SSXB10. These theoretical models are then brought into the real world through chemical synthesis, where molecules that fit the predicted structures and properties are created. After synthesis, the compounds undergo rigorous biochemical assays designed to assess their efficacy in interacting with SSXB10. These tests aim to evaluate the binding affinity and ascertain the degree to which the compound influences the activity of SSXB10, as well as its selectivity to ensure specificity of action. Despite their varied structures, which can range from relatively simple to highly complex, SSXB10 inhibitors uniformly share the ability to modulate the function of the target molecule, SSXB10, through direct molecular interaction.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR inhibitor that blocks the epidermal growth factor receptor, which can indirectly decrease the activity of SSXB10 by inhibiting downstream signaling events that may be responsible for its activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that can disrupt the mTOR signaling pathway, potentially leading to reduced transcriptional and translational events crucial for SSXB10 function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
This is a PI3K inhibitor that can impede the PI3K/Akt pathway, possibly leading to decreased phosphorylation and activation of proteins that control the function of SSXB10. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor that can inhibit the MAPK/ERK pathway, potentially leading to the downregulation of factors that contribute to the correct localization or function of SSXB10. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that can inhibit stress-activated protein kinase pathways, thereby potentially reducing the activity of proteins that may regulate SSXB10. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor known to impede the PI3K/Akt pathway, which could lead to a reduction in the activity of SSXB10 by affecting downstream signaling molecules. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a CDK4/6 inhibitor that may decrease cell cycle progression, potentially influencing the expression level or activity of SSXB10 in the process of cell division. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor that can alter chromatin structure and gene expression patterns, thereby indirectly affecting the function of SSXB10 by changing the transcriptional landscape. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor and could lead to altered protein degradation pathways, affecting the stability and turnover of SSXB10. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that can affect various signaling pathways, potentially leading to reduced activity or expression of SSXB10 by disrupting its activation signals. | ||||||